[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:mucopolysaccharidosis-type-iiib":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":30,"states":31},"Mucopolysaccharidosis Type IIIB",3,0,[8,16,24],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07640984","A Phase I\u002FII Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)",[12],"Phase 1\u002FPhase 2","NOT_YET_RECRUITING","2026-08-26T02:16:44.178623Z","2026-06-14T18:39:22.259019Z",{"nct_id":17,"title":18,"phases":19,"status":21,"updated_at":22,"content_modified":23},"NCT05492799","Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE",[20],"Phase 4","ENROLLING_BY_INVITATION","2026-08-26T02:17:22.949982Z","2026-06-16T05:54:08.034247Z",{"nct_id":25,"title":26,"phases":27,"status":21,"updated_at":28,"content_modified":29},"NCT05368038","ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program",[],"2026-08-26T02:18:52.966503Z","2026-06-16T05:54:08.030731Z",[],[]]